Link Dinan, T
SURMOUNT-1 (N=2,539) showed mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses respectively at 72 weeks, compared to 3.1% with placebo
GHRH analogues (CJC-1295, tesamorelin) are structurally modified versions of native GHRH
N Engl J Med 387(3):205216 [DOI] [PubMed] [Google Scholar] 24.Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I (2025) SURMOUNT-1 investigators
This option provides a medically supervised pathway for Type 1 patients to explore GLP-1 therapy at predictable cost, with the dose adjusted as clinically neededwhile your dose may increase, your monthly price remains flat
Our team has worked with hundreds of patients navigating lipotropic protocols